Dianne C. Whitfield, Chief HR Officer at Tarsus Pharmaceuticals, sold 12,274 shares valued at about $839,000 between March 17-19, 2026, to cover tax withholding from vested RSUs. This sale represented roughly 26% of her direct holdings and was a routine, non-discretionary transaction unrelated to company fundamentals. Tarsus reported strong 2025 sales growth, driven by its lead drug XDEMVY, with revenues doubling to $451 million and narrowing net losses to $66 million. Investors should focus on the company's advancing pipeline and commercial execution rather than this insider sale.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
